BACKGROUND AND OBJECTIVES: Intradialytic hypertension may be caused by an impaired endothelial cell response to hemodialysis. Carvedilol has been shown to improve endothelial cell function in vivo and to block endothelin-1 release in vitro. This study hypothesized that carvedilol would improve endothelial cell function and reduce the occurrence of intradialytic hypertension. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A prospective 12-week pilot study of carvedilol titrated to 50 mg twice daily was performed among 25 hemodialysis participants with intradialytic hypertension. Each patient served as his or her own control. Paired tests were used to analyze changes in BP and endothelial cell function--assessed by flow-mediated vasodilation, endothelial progenitor cells (aldehyde dehydrogenase bright activity and CD34(+)CD133(+)), asymmetric dimethylarginine, and endothelin-1--from baseline to study end. RESULTS: Flow-mediated vasodilation was significantly improved with carvedilol (from 1.03% to 1.40%, P=0.02). There was no significant change in endothelial progenitor cells, endothelin-1, or asymmetric dimethylarginine. Although prehemodialysis systolic BP was unchanged (144-146 mmHg, P=0.5), posthemodialysis systolic BP, 44-hour ambulatory systolic BP, and the frequency of intradialytic hypertension decreased with carvedilol (159-142 mmHg, P<0.001; 155-148 mmHg, P=0.05; and 77% [4.6 of 6] to 28% [1.7 of 6], P<0.001, respectively). CONCLUSIONS: Among hemodialysis participants with intradialytic hypertension, targeting endothelial cell dysfunction with carvedilol was associated with modest improvements in endothelial function, improved intradialytic and interdialytic BP, and reduced frequency of intradialytic hypertension. Randomized controlled trials are required to confirm these findings.
BACKGROUND AND OBJECTIVES: Intradialytic hypertension may be caused by an impaired endothelial cell response to hemodialysis. Carvedilol has been shown to improve endothelial cell function in vivo and to block endothelin-1 release in vitro. This study hypothesized that carvedilol would improve endothelial cell function and reduce the occurrence of intradialytic hypertension. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A prospective 12-week pilot study of carvedilol titrated to 50 mg twice daily was performed among 25 hemodialysis participants with intradialytic hypertension. Each patient served as his or her own control. Paired tests were used to analyze changes in BP and endothelial cell function--assessed by flow-mediated vasodilation, endothelial progenitor cells (aldehyde dehydrogenase bright activity and CD34(+)CD133(+)), asymmetric dimethylarginine, and endothelin-1--from baseline to study end. RESULTS: Flow-mediated vasodilation was significantly improved with carvedilol (from 1.03% to 1.40%, P=0.02). There was no significant change in endothelial progenitor cells, endothelin-1, or asymmetric dimethylarginine. Although prehemodialysis systolic BP was unchanged (144-146 mmHg, P=0.5), posthemodialysis systolic BP, 44-hour ambulatory systolic BP, and the frequency of intradialytic hypertension decreased with carvedilol (159-142 mmHg, P<0.001; 155-148 mmHg, P=0.05; and 77% [4.6 of 6] to 28% [1.7 of 6], P<0.001, respectively). CONCLUSIONS: Among hemodialysis participants with intradialytic hypertension, targeting endothelial cell dysfunction with carvedilol was associated with modest improvements in endothelial function, improved intradialytic and interdialytic BP, and reduced frequency of intradialytic hypertension. Randomized controlled trials are required to confirm these findings.
Authors: Mary C Corretti; Todd J Anderson; Emelia J Benjamin; David Celermajer; Francois Charbonneau; Mark A Creager; John Deanfield; Helmut Drexler; Marie Gerhard-Herman; David Herrington; Patrick Vallance; Joseph Vita; Robert Vogel Journal: J Am Coll Cardiol Date: 2002-01-16 Impact factor: 24.094
Authors: Jonathan M Hill; Gloria Zalos; Julian P J Halcox; William H Schenke; Myron A Waclawiw; Arshed A Quyyumi; Toren Finkel Journal: N Engl J Med Date: 2003-02-13 Impact factor: 91.245
Authors: Dominic S C Raj; Brad Vincent; Keith Simpson; Etsuro Sato; Kimberly L Jones; Tomas C Welbourne; Moshe Levi; Vallabh Shah; Pedro Blandon; Philip Zager; Richard A Robbins Journal: Kidney Int Date: 2002-02 Impact factor: 10.612
Authors: M Cirit; F Akçiçek; E Terzioğlu; C Soydaş; E Ok; C F Ozbaşli; A Başçi; E J Mees Journal: Nephrol Dial Transplant Date: 1995 Impact factor: 5.992
Authors: G Bazzato; U Coli; S Landini; S Lucatello; A Fracasso; P Morachiello; F Righetto; F Scanferla Journal: Contrib Nephrol Date: 1984 Impact factor: 1.580
Authors: Sola Aoun Bahous; Antoine Stephan; Wadad Barakat; Jacques Blacher; Roland Asmar; Michel E Safar Journal: Kidney Int Date: 2004-10 Impact factor: 10.612
Authors: Noyan Gokce; John F Keaney; Liza M Hunter; Michael T Watkins; Zoran S Nedeljkovic; James O Menzoian; Joseph A Vita Journal: J Am Coll Cardiol Date: 2003-05-21 Impact factor: 24.094
Authors: Gérard M London; Bruno Pannier; Mohsen Agharazii; Alain P Guerin; Francis H M Verbeke; Sylvain J Marchais Journal: Kidney Int Date: 2004-02 Impact factor: 10.612
Authors: Tariq Shafi; Stephen M Sozio; Karen J Bandeen-Roche; Patti L Ephraim; Jason R Luly; Wendy L St Peter; Aidan McDermott; Julia J Scialla; Deidra C Crews; Navdeep Tangri; Dana C Miskulin; Wieneke M Michels; Bernard G Jaar; Charles A Herzog; Philip G Zager; Klemens B Meyer; Albert W Wu; L Ebony Boulware Journal: J Am Soc Nephrol Date: 2014-01-02 Impact factor: 10.121
Authors: Amith Roy Shamir; Ameet Karembelkar; Jonathan Yabes; Yi Yao; Dana Miskulin; Jennifer Gassman; David Ploth; Lavinia Negrea; Susan Paine; Mahboob Rahman; Raymond Y Kwong; Philip Zager; Manisha Jhamb Journal: Kidney Blood Press Res Date: 2018-05-30 Impact factor: 2.687